ReviewMolecular diversity2026
Exploring molecular frameworks for modulating NLRP3-driven neuroinflammation in Alzheimer's disease.
Review in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Alzheimer's disease (AD) is marked by a gradual decline in cognitive abilities, primarily resulting from the degeneration of the cerebral cortex and hippocampus. This degeneration is closely associated with the abnormal buildup of amyloid beta (Aβ) plaques and hyperphosphorylated tau proteins, which initiate a chronic neuroinflammatory response arbitrated by the initiation of the brain's resident immune cells. The NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome is pivotal in regulating this inflammatory response. Chronic neuroinflammation results in the release of pro-inflammatory cytokines, such as interleukin-1β -1β (IL-1β), which disrupt neuronal function, hinder synaptic plasticity, and contribute to neuronal death. Additionally, neuroinflammation compromises the blood–brain barrier's (BBB) integrity, allowing peripheral immune cells to worsen the inflammatory response, leading to neurodegeneration and impaired neurogenesis, which further exacerbates cognitive deficits. Cellular stressors such as mitochondrial impairment, elevated reactive oxygen species (ROS), and lysosomal rupture initiate inflammasome activation, leading to the release of the pro-inflammatory cytokines IL-1β and interleukin-18 (IL-18). Current therapeutic approaches primarily focus on reducing Aβ levels, but their effectiveness on cognitive outcomes remains limited, highlighting the necessity for innovative strategies that target neuroinflammation. This review underscores the potential of various chemical scaffolds in developing novel treatments for AD. By building on these insights, preclinical research could further assess their safety, effectiveness, and ability to penetrate the BBB, along with optimal formulation strategies paving the way for clinical trials. This contributes to the growing field of inflammasome-targeted AD therapies, which may combine with existing treatments for synergistic effects, ultimately improving prognosis for the millions affected by AD.
Indexed as
Identifiers
41764697What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.